Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems

Journal of Neurochemistry

Volumn 71, Issue 3, 1998, Pages 1158-1167

  Azzi, Mounia ^a   Betancur, Catalina ^a   Sillaber, Inge ^b   Spanagel, Rainer ^b   Rostène, William ^a   Bérod, Anne ^a,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Corticosterone; Dopamine; Medial prefrontal cortex; Neurotensin; Nucleus accumbens; SR 48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CORTICOSTERONE; DOPAMINE; MESSENGER RNA; NEUROTENSIN RECEPTOR ANTAGONIST; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; DOPAMINERGIC SYSTEM; DRUG EFFECT; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC CORTEX; MALE; MESENCEPHALON; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RAT;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0031868452     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71031158.x     Document Type: Article

References (62)

1. Azzi M., Boudin H., Mahmudi N., Pélaprat D., Rostène W., and Bérod A. (1996) In vivo regulation of neurotensin receptors following long-term pharmacological blockade with a specific receptor antagonist. Mol. Brain Res. 42, 213-221.
2. Barden N., Reul J. M. H., and Holsboer F. (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci. 18, 6-14.
3. Bayer V. E., Towle A. C., and Pickel V. M. (1991) Ultrastructural localization of neurotensin-like immunoreactivity within dense core vesicles in perikarya, but not terminals, colocalizing tyrosine hydroxylase in the rat ventral tegmental area. J. Comp. Neurol. 311, 179-196.
4. Beart P. M. and Gundlach A. L. (1980) 3.4-Dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effect and evidence for somatodendritic mechanisms. Br. J. Pharmacol. 69, 241-247.
5. Beitner-Johnson D. and Nestler E. J. (1991) Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopaminergic brain reward regions. J. Neurochem. 57, 344-347.
6. Betancur C., Rostène W., and Bérod A. (1997) Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. Mol. Brain Res. 44, 334-340.
7. Brun P., Steinberg R., Le Fur G., and Soubrié P. (1995) Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. J. Neurochem. 64, 2073-2079.
8. Burgevin M. C., Castel M. N., Quarteronet D., Chevet T., and Laduron P. M. (1992) Neurotensin increases tyrosine hydroxylase mRNA-positive neurons in the substantia nigra after retrograde axonal transport. Neuroscience 49, 627-633.
9. Cador M., Kelley A. E., Le Moal M., and Stinus L. (1985) Behavioral analysis of the effect of neurotensin injected into the ventral mesencephalon on the investigatory and spontaneous motor behavior in the rat. Psychopharmacology (Berl.) 85, 187-196.
10. Cador M., Rivet J. M., Kelley A. E., Le Moal M., and Stinus L. (1989) Substance P, neurotensin and enkephalin injections into the ventral tegmental area: comparative study on dopamine turnover in several forebrain structures. Brain Res. 486, 357-363.
11. Casolini P., Kabbaj M., Piazza P. V., Angelucci L., Simon H., Le Moal M., and Maccari S. (1994) The D1 dopamine agonist SKF 38393, but not the D2 agonist LY 171555, decreases the affinity of type II corticosteroid receptors in rat hippocampus and ventral striatum. Neuroscience 60, 939-943.
12. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Ferrara P., and Caput D. (1996) Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386, 91-94.
13. Elliot P. J. and Nemeroff C. B. (1986) Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine-induced locomotor activity. Neurosci. Lett. 68, 239-244.
14. Ervin G. N., Birkemo L. S., Nemeroff C. B., and Prange A. J. Jr. (1981) Neurotensin blocks certain amphetamine-induced behaviors. Nature 291, 73-76.
15. 11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Res. 534, 243-250.
16. Grima B., Lamouroux A., Blanot F., Faucon Biguet N., and Mallet J. (1985) Complete coding sequence of rat tyrosine hydroxylase gene. Proc. Natl. Acad. Sci. USA 82, 617-621.
17. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J. C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., Pélaprat D., Labbé-Jullié C., Mazella J., Soubrié P., Maffrand J. P., Rostène W., Kitabgi P., and Le Fur G. (1993) Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of neurotensin receptor. Proc. Natl. Acad. Sci. USA 90, 65-69.
18. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., Poncelet M., Steinberg R., Suaud-Chagny M. F., Santucci V., Vita N., Pecceu F., Labbé-Jullié C., Kitabgi P., Soubrié P., Le Fur G., and Maffrand J. P. (1997) Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 280, 802-812.
19. Hantraye P., Guibert B., Faucon Biguet N., Lavergne A., and Leviel V. (1994) TH mRNA over-expression in rats with chronic excitotoxic striatal lesions. Neuroreport 5, 2621-2624.
20. Härfstrand A., Fuxe K., Cintra A., Agnati L. F., Zini I., Wikström A. C., Okret S., Yu Z. Y., Goldstein M., Steinbuch H., Verhofstad A., and Gustafsson J. A. (1986) Glucocorticoid receptor immunoreactivity in monoaminergic neurons in rat brain. Proc. Natl. Acad. Sci. USA 83, 9779-9783.
21. Hökfelt T., Everitt B. J., Theodorsson-Norheim E., and Goldstein M. (1984) Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol. 222, 543-559.
22. Joyce J. N. (1993) The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology (Berl.) 112, S16-S34.
23. Kabbaj M., Piazza P. V., Simon H., Le Moal M., and Maccari S. (1995) Opposite effects on hippocampal corticosteroid receptors induced by stimulation of beta and alpha 1 noradrenergic receptors. Neuroscience 66, 539-545.
24. Kabbaj M., Le Moal M., and Maccari S. (1996) Hippocampal type I and type II corticosteroid receptors are differentially regulated by chronic prazosin treatment. Neuroscience 73, 963-970.
25. Kalivas P. W. (1993) Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18, 75-113.
26. Kalivas P. W. and Duffy P. (1990) Effect of acute and daily injection of neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J. Neurosci. 10, 2940-2949.
27. Kalivas P. W., Nemeroff C. B., and Prange A. J. Jr. (1981) Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area. Brain Res. 29, 525-529.
28. Kalivas P. W., Burgess P. W., Nemeroff C. B., and Prange A. J. Jr. (1983) Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area. Neuroscience 8, 495-505.
29. Kalivas P. W., Nemeroff C. B., and Prange A. J. Jr. (1984) Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 11, 919-930.
30. Kalivas P. W., Duffy P., and Barrow J. (1989) Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther. 251, 378-387.
31. Kasckow J. and Nemeroff C. B. (1991) The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regul. Pept. 36, 153-164.
32. Koob G. F. (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13, 177-184.
33. Laitinen K., Crawley A. N., Mefford I. N., and de Witte P. (1990) Neurotensin and cholecystokinin microinjected into the ventral tegmental area modulate microdialysate concentrations of dopamine and metabolites in the posterior nucleus accumbens. Brain Res. 523, 342-346.
34. Leviel V., Fayada C., Guibert B., Chaminade M., Machek G., Mallet J., and Faucon Biguet N. (1990) Short-and long-term alterations of gene expression in limbic structures by repeated electroconvulsive-induced seizures. J. Neurochem. 54, 899-904.
35. Leviel V., Guibert B., Mallet J., and Faucon Biguet N. (1991) Induction of tyrosine hydroxylase in the rat substantia nigra by local injection of forskolin. J. Neurosci. Res. 30, 427-432.
36. Linthorst A. C. E., Flachskamm C., Müller-Preuss P., Holsboer F., and Reul J. M. H. M. (1995) Effect of bacterial endotoxin and interleukin-1β on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J. Neurosci. 15, 2920-2934.
37. Nemeroff C. B., Luttinger D., Hernandez D. E., Mailman R. B., Mason G. A., Davis S. D., Widerlov E., Frye G. D., Kilt C. A., Beaumont K., Breese G. R., and Prange A. J. Jr. (1983) Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 225, 337-345.
38. Nicot A., Rostène W., and Bérod A. (1995) Differential expression of neurotensin mRNA in the dopaminergic cell groups of the rat diencephalon and mesencephalon. J. Neurosci. Res. 40, 667-674.
39. Nicot A., Rowe W. B., de Kloet E. R., Betancur C., Jessop D. S., Lightman S. L., Quirion R., Rostène W., and Bérod A. (1997) Endogenous neurotensin regulates hypothalamic-pituitary-adrenal axis activity and peptidergic neurons in the rat hypothalamic paraventricular nucleus. J. Neuroendocrinol. 9, 263-269.
40. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edit. Academic Press, Sydney.
41. Piazza P. V., Barrot M., Rougé-Pont F., Marinelli M., Maccari S., Abrous D. N., Simon H., and Le Moal M. (1996a) Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proc. Natl. Acad. Sci. USA 93, 15445-15450.
42. Piazza P. V., Rougé-Pont F., Deroche V., Maccari S., Simon H., and Le Moal M. (1996b) Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc. Natl. Acad. Sci. USA 93, 8716-8720.
43. Rivest R., Jolicoeur F. B., and Marsden C. A. (1991) Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo. Neuropharmacology 30, 25-33.
44. Rowe W. B., Nicot A., Sharma S., Gully D., Walker C. D., Rostène W. H., Meaney M. J., and Quirion R. (1997) Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity. Neuroendocrinology 66, 75-85.
45. Santucci V., Gueudet C., Steinberg R., Le Fur G., and Soubrié P. (1997) Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse 26, 370-380.
46. 3H-neurotensin binding site in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 333, 400-405.
47. Seroogy K. B., Mehta A., and Fallon J. H. (1987) Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain. Exp. Brain Res. 68, 277-289.
48. Sesack S. R. and Pickel V. M. (1992) Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J. Comp. Neurol. 320, 145-160.
49. Shi W. X. and Bunney B. S. (1991) Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity. Brain Res. 543, 315-321.
50. Spanagel R., Herz A., and Shippenberg T. S. (1990) The effect of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55, 1734-1740.
51. Steinberg R., Brun P., Fournier M., Souilhac J., Rodier D., Mons G., Terranova J. P., Le Fur G., and Soubrié P. (1994) SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 59, 921-929.
52. Steinberg R., Brun P., Souilhac J., Bougault I., Leyris R., Le Fur G., and Soubrié P. (1995) Neurochemical and behavioural effects of neurotensin vs [D-Tyr(11)]neurotensin on mesolimbic dopaminergic function. Neuropeptides 28, 43-50.
53. Stowe Z. N. and Nemeroff C. B. (1991) The electrophysiological actions of neurotensin in the central nervous system. Life Sci. 49, 987-1002.
54. Studler J. M., Kitabgi P., Tramu G., Hervé D., Glowinski J., and Tassin J. P. (1988) Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Peptides 11, 95-100.
55. Szigethy E. and Beaudet A. (1989) Correspondence between high affinity neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area: a combined radioautographic and immunohistochemical light microscopic study. J. Comp. Neurol. 279, 487-498.
56. Taber M. T. and Fibiger H. C. (1995) Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J. Neurosci. 15, 3896-3904.
57. Tanaka K., Masu M., and Nakanishi S. (1990) Structure and functional expression of the cloned rat neurotensin receptor. Neuron 4, 847-854.
58. Tanganelli S., O'Connor W. T., Ferraro L., Bianchi C., Benni L., Ungerstedt U., and Fuxe K. (1994) Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience 60, 649-657.
59. Vrana S. L., Vrana K. E., Koves T. R., Smith J. E., and Dworkin S. I. (1993) Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J. Neurochem. 61, 2262-2268.
60. Wagstaff J. D., Bush L. G., Gibb J. W., and Hanson G. R. (1994) Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res. 665, 237-244.
61. White F. J. (1996) Synaptic regulation of mesocorticolimbic dopamine neurons. Annu. Rev. Neurosci. 19, 405-436.
62. Yau J. L. W., Dow R. C., Fink G., and Seckl J. R. (1992) Medial septal cholinergic lesions increase hippocampal mineralocorticoid and glucocorticoid receptor messenger RNA expression. Brain Res. 577, 155-160.